================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------------
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): May 8, 2001
--------------------
STEMCELLS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 0-19871 94-3078125
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation) Identification Number)
2155 PORTER DRIVE
PALO ALTO, CALIFORNIA 94304
(Address, of principal executive offices, including zip code)
(650) 475-3100
(Registrant's Telephone number including area code)
--------------------
================================================================================
Item 5. OTHER EVENTS
On April 30, 2001, StemCells, Inc. issued a press release announcing that
it had sold all of its remaining founder's shares in Swiss Modex Therapeutics,
Ltd. (SWX New Market: MDXN) in a private placement. StemCells, Inc. sold 103,577
shares at a net price of 87.30 CHF (Swiss francs) per share, or a total sum of
approximately US $5,200,000. A copy of this press release is attached to this
Current Report on Form 8-K as Exhibit 99.1.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
STEMCELLS, INC.
By /s/ George Koshy
-------------------------------------
George Koshy
Controller and Acting Chief
Financial Officer
Date: May 7, 2001
EXHIBIT INDEX
99.1 Press Release dated April 30, 2001